Vedanta Biosciences has appointed Lisa Schopf as head of preclinical development and Erik Spek as head of intellectual property.
Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases using technology that mines the human microbiome for potent pharmaceutical products.
Schopf formerly served as the senior director of preclinical development at Kala Pharmaceuticals and has over 20 years of industry experience.
Spek joins from Epizyme, a clinical stage biopharmaceutical company focused on epigenetic targets, where he worked as director of intellectual property.
Bernat Olle, CEO of Vedanta Biosciences, said: “We are delighted to welcome Lisa and Erik to the team. This is an exiting time for Vedanta, and their experience and leadership will be invaluable as we advance our pipeline of drug candidates and scale our discovery platform.”